Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA Approves Expanded Use of Treatment for PatientsWith Severe Alzheimer’s Disease

By Pharmaceutical Processing | October 17, 2006

The FDA has approved Aricept (donepezil hydrochloride) for the treatment of severe dementia in patients with Alzheimer’s Disease. Aricept was previously approved for the treatment of mild to moderate dementia of the Alzheimer’s type. It now becomes the first product approved for the treatment of all degrees of severity of the disease. “Alzheimer’s Disease is a devastating, age-associated brain disorder that affects an estimated 4.5 million Americans — and, as our population grows older, this number is expected to multiply,” said Dr. Steven Galson, director of the Center for Drug Evaluation and Research. “Today’s approval makes available another treatment for those with severe dementia.”FDA approved Aricept to treat patients with mild to moderate Alzheimer’s Disease ten years ago after two clinical trials demonstrated that patients receiving the drug performed better than patients who received placebo. Today’s approval is based on two additional randomized, placebo-controlled, 24-week clinical studies conducted in Sweden and Japan in more than 500 patients with severe Alzheimer’s Disease. In these studies, the effectiveness of treatment with Aricept was determined by evaluating the patients’ cognitive functions such as memory, language, orientation and attention, as well as their overall functioning. The results showed that patients on Aricept performed better on both measures compared to placebo. Aricept is manufactured by Eisai Inc., Teaneck, N.J.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards